奥氮平预防化疗所致乳腺癌患者爆发性呕吐的临床观察  

Clinical Observation of Olanzapine in the Prevention of Explosive Chemotherapy-induced Vomiting in the Patients with Breast Cancer

作　　者：王先国[1] 陈景华[1] 李杰[1] 李宇[1] 周远[1] 张山燕 

机构地区：[1]泰安市肿瘤防治院化疗二科,山东泰安271000

出　　处：《肿瘤基础与临床》2015年第1期62-64,共3页journal of basic and clinical oncology

摘　　要：目的探讨奥氮平预防TAC方案所致乳腺癌患者爆发性呕吐的疗效及安全性。方法入组在TAC方案化疗第1周期发生爆发性呕吐的40例乳腺癌患者,于第2周期化疗前给予口服奥氮平及常规预防止吐处理,并观察其预防效果。结果 40例乳腺癌患者应用奥氮平后恶心呕吐评分较应用前明显下降[(10.2±0.8)vs(17.2±1.2),P<0.05],其中45%的患者未再发生呕吐。主要毒副反应为乏力和头晕,发生率分别为35.0%和30.0%。结论奥氮平可有效减少TAC方案化疗所致爆发性呕吐的发生,改善患者化疗后的恶心呕吐症状。Objective To evaluate the efficacy and safety of olanzapine in the prevention of explosive chemotherapy-induced vomiting in the patients with breast cancer treated with TAC regimen chemotherapy. Methods Forty patients with breast cancer occurred explosive chemotherapy-induced vomiting in the first chemotherapy cycle, received the TAC regimen chemotherapy and olanzapine before the second chemotherapy cycle, and the prevention efficacy were observed. Results The vomiting scores of the 40 patients with breast cancer after olanzapine were significantly lower than those before olanzapine [ （ 10.2±0.8） vs （ 17.2±1.2） ,P 〈0.05] ,45% of the patients no longer had vomiting after olanzapine. The main toxicities were fatigue （35.0%） and dizziness （ 30.0% ）. Conclusion Olanzapine can effectively reduce the incidence of explosive TAC regimen chemotherapy-induced vomiting, and improve the symptom of nausea and vomiting in the patients with breast cancer.

关 键 词：奥氮平 化疗 乳腺癌 爆发性呕吐 

分 类 号：R730.53[医药卫生—肿瘤] R737.9[医药卫生—临床医学]